Sei Investments Co. Has $1.14 Million Stake in Organon & Co. $OGN

Sei Investments Co. raised its stake in Organon & Co. (NYSE:OGN) by 82.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 190,057 shares of the company’s stock after acquiring an additional 85,657 shares during the period. Sei Investments Co.’s holdings in Organon & Co. were worth $1,139,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of OGN. Vanguard Group Inc. lifted its holdings in shares of Organon & Co. by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after acquiring an additional 987,979 shares during the period. State Street Corp grew its holdings in shares of Organon & Co. by 2.8% in the 4th quarter. State Street Corp now owns 9,597,761 shares of the company’s stock worth $68,816,000 after purchasing an additional 262,185 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after purchasing an additional 4,394,814 shares during the last quarter. Private Management Group Inc. grew its holdings in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Organon & Co. by 55.2% during the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Trading Up 0.1%

OGN opened at $13.66 on Thursday. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.70. The stock has a market capitalization of $3.59 billion, a PE ratio of 17.74, a PEG ratio of 1.26 and a beta of 1.55. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 8.43. The firm has a 50-day moving average price of $13.51 and a two-hundred day moving average price of $10.68.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is currently 10.39%.

Analyst Upgrades and Downgrades

OGN has been the topic of a number of recent analyst reports. BNP Paribas Exane restated a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Finally, Weiss Ratings cut shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.